Martin Edwards

Dr. Edwards is currently Chairman of KalVista Pharmaceuticals, Inc. and a member of the Board of Directors of Reata Pharmaceuticals Inc., Morphic Therapeutics Inc., Verona Pharma PLC, and Inozyme Pharma, Inc. He recently retired as Senior Partner at Novo Holdings A/S. Prior to joining Novo Holdings A/S, Dr. Edwards was the Chief Executive Officer of ReNeuron Holdings. Previously, Dr. Edwards was Corporate Vice President and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development. Earlier he worked as Vice President of Pharmacology and Medical Affairs for ZymoGenetics Inc. and then as Senior Vice President for Medical Affairs at Novo Nordisk USA. Dr. Edwards trained in physiology and medicine in Manchester, UK. He was elected as a Member of the Royal Colleges of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine, and holds an MBA from the University of Warwick.